Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

Glp-1s cover a variety of drugs that are commonly used for weight loss, such as Ozempic, Wegovy and Mounjaro. And West Virginians used them at the highest rate ...

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured ...

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...